<unk>  is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company<unk> l-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.
BIA 10-2474
ALC-0159
MDX-1097
UB-612
LSM-775
ALC-0315
ICI-85966
NHS 24